Table 1 Patients characteristics
All (n = 179) | ART (n = 42) | SRT (n = 137) | ||
|---|---|---|---|---|
Age [years] | 67 (range: 42–85) | 67 (range: 42–75) | 66 (range: 49–85) | |
Initial PSA level [ng/mL] [19] | ||||
Low risk (< 10) | 111 (62.0%) | 22 (52.4%) | 89 (65.0%) | |
Intermediate risk (10–20) | 35 (19.6%) | 10 (23.8%) | 25 (18.2%) | |
High risk (> 20) | 30 (16.8%) | 10 (23.8%) | 20 (14.7%) | |
Missing | 3 (1.7%) | 0 (0.0%) | 3 (2.2%) | |
ISUP Grading (Gleason score) [20] | ||||
Group 1 (≤ 6) | 26 (14.5%) | 2 (4.8%) | 24 (17.5%) | |
Group 2 (3 + 4 = 7) | 53 (29.6%) | 8 (19.0%) | 45 (32.8%) | |
Group 3 (4 + 3 = 7) | 45 (25.1%) | 14 (33.3%) | 31 (22.6%) | |
Group 4 (8) | 27 (15.1%) | 6 (14.3%) | 21 (15.3%) | |
Group 5 (≥ 9) | 24 (13.4%) | 12 (28.6%) | 12 (8.8%) | |
Missing | 4 (2.3%) | 0 (0.0%) | 4 (2.9%) | |
Postoperative T-stage [19] | ||||
Low risk | pT2a | 16 (8.9%) | 0 (0.0%) | 16 (11.7%) |
Intermediate risk | pT2b | 9 (5.0%) | 1 (2.4%) | 8 (5.8%) |
pT2c | 56 (31.3%) | 4 (9.5%) | 52 (38.0%) | |
High risk | pT3a | 46 (25.7%) | 17 (40.5%) | 29 (21.2%) |
pT3b | 46 (25.7%) | 20 (47.6%) | 26 (19.0%) | |
pT4 | 6 (3.4%) | 0 (0.0%) | 6 (4.4%) | |
Postoperative nodal status | ||||
Negative (pN0) | 157 (87.7%) | 29 (69.0%) | 128 (93.4%) | |
Positive (pN1) | 22 (12.3%) | 13 (31.0%) | 9 (6.6%) | |
Surgical margins | ||||
R0 | 93 (52.0%) | 10 (23.8%) | 83 (60.6%) | |
R1 | 86 (48.0%) | 32 (76.2%) | 54 (39.4%) | |
Omission of ADT (additive or adjuvant ADT) | 35 (19.6%) | 9 (21.4%) | 26 (19.0%) | |
Median time of ADT [months] | 13 (range:1–140) | 17 (range: 4–32) | 13 (range: 1–140) | |
RT technique | ||||
3D-CRT | 37 (20.7%) | 8 (19.0%) | 29 (21.1%) | |
Dynamic IMRT | 10 (5.6%) | 1 (2.4%) | 9 (6.6%) | |
VMAT | 113 (63.1%) | 30 (71.4%) | 83 (60.6%) | |
Helical IMRT | 19 (10.6%) | 3 (7.2%) | 16 (11.7%) | |
Median total dose [Gy] | 64.0 (range: 52.0–70.2) | 60.0 (range: 52.0–64.8) | 64.0 (range: 59.4–70.2) | |
Median follow-up [months] | 32.5 (range: 1.4–128.0) | 36.5 (range: 1.4–102.5) | 31.5 (range: 1.5–128.0) | |